Search

Displaying results 5821 - 5830 of 10000 in total
  1. Drug

    Hordeum vulgare pollen

    go.drugbank.com/drugs/DB10961
    Approved

    Hordeum vulgare pollen is mainly used in allergenic testing.

  2. Drug

    Pseudotsuga menziesii pollen

    go.drugbank.com/drugs/DB10986
    Approved

    Pseudotsuga menziesii pollen is mainly used in allergenic testing.

  3. Drug

    Maclura pomifera pollen

    go.drugbank.com/drugs/DB10988
    Approved

    Maclura pomifera pollen is mainly used in allergenic testing.

  4. Drug

    M0002

    go.drugbank.com/drugs/DB05091
    Investigational

    M0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys. … It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes.

  5. Drug

    Plinabulin

    go.drugbank.com/drugs/DB05992
    Investigational

  6. Drug

    AVAC

    go.drugbank.com/drugs/DB05441
    Experimental

    It has been tested in uses related to asthma and in treating eczema and atopic dermatitis. … [Mycobacterium vaccae] is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate

  7. Drug

    Lisavanbulin

    go.drugbank.com/drugs/DB15224
    Investigational

    Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).

  8. Drug

    Giripladib

    go.drugbank.com/drugs/DB15426
    Investigational

    Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee).

  9. Drug

    Otilimab

    go.drugbank.com/drugs/DB06303
    Investigational

    Investigated for the treatment of osteoarthritis and rheumatoid arthritis (RA).

  10. Drug

    Tesaglitazar

    go.drugbank.com/drugs/DB06536
    Investigational

    Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. … Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.